Procyrion Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
2ndary - Private
- Investors
-
4
Procyrion General Information
Description
Developer of a percutaneous circulatory support device with an initial indication of decongesting acute decompensated heart failure patients who are diuretic-resistant. The company's device is designed to rest the heart by reducing afterload while simultaneously improving blood flow to the kidneys, enabling cardiologists to treat heart failure patients who are too sick for medication alone.
Contact Information
Website
www.procyrion.comCorporate Office
- 3900 Essex Lane
- Suite 850
- Houston, TX 77027
- United States
Corporate Office
- 3900 Essex Lane
- Suite 850
- Houston, TX 77027
- United States
Procyrion Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 10. Later Stage VC (Series E) | 05-Feb-2024 | Completed | Clinical Trials - Phase 1 | |||
| 9. Later Stage VC (Series D) | 03-Jul-2019 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC (Series C) | 30-Jan-2018 | Completed | Clinical Trials - Phase 1 | |||
| 7. Grant | 24-Jan-2017 | Completed | Clinical Trials - Phase 1 | |||
| 6. Accelerator/Incubator | 02-Mar-2016 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series B1) | 08-Oct-2015 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series A2) | 03-Dec-2014 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 26-Jun-2014 | $50K | $3.15M | Completed | Clinical Trials - Phase 1 | |
| 2. Later Stage VC (Series A) | 20-Jan-2014 | $3.15M | $3.15M | Completed | Clinical Trials - Phase 1 |
Procyrion Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E-2 | ||||||||
| Series E-1 | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series A2 | 406,250 | $0.001000 | $1.6 | $1.6 | 1x | $1.6 | 0.61% | |
| Series A1 | 1,284,480 | $0.001000 | $0.96 | $0.96 | 1x | $0.96 | 1.91% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Procyrion Comparisons
Industry
Financing
Details
Procyrion Competitors (5)
One of Procyrion’s 5 competitors is Revamp Medical, a Venture Capital-Backed company based in Netania, Israel.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Revamp Medical | Venture Capital-Backed | Netania, Israel | ||||
| Abiomed | Corporate Backed or Acquired | Danvers, MA | ||||
| NuPulse | Venture Capital-Backed | Raleigh, NC | ||||
| Boston Scientific | Corporation | Marlborough, MA | ||||
| Colibri Heart Valve | Venture Capital-Backed | Louisville, CO |
Procyrion Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Procyrion Patents
Procyrion Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260131135-A1 | Hermetic driveline for implantable medical devices | Pending | 08-Nov-2024 | ||
| US-20260257056-A1 | Modular assembly of implantable electromotive micromechanical blood pump | Pending | 08-Nov-2024 | ||
| US-20260131132-A1 | Modular strut assembly for intravascular devices | Pending | 08-Nov-2024 | ||
| WO-2025255135-A1 | Modular bearings for blood flow assist systems | Pending | 05-Jun-2024 | ||
| AU-2023390008-A1 | Percutaneous mechanical circulatory support device | Pending | 07-Dec-2022 | A61M60/139 |
Procyrion Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Procyrion Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bluebird Ventures | Venture Capital | Minority | ||
| Boston Scientific Corporation 401(k) Retirement Savings Plan | Limited Partner | Minority | ||
| NIH Seed | Not-For-Profit Venture Capital | |||
| Fannin | Venture Capital | Minority |
Procyrion FAQs
-
When was Procyrion founded?
Procyrion was founded in 2005.
-
Where is Procyrion headquartered?
Procyrion is headquartered in Houston, TX.
-
What is the size of Procyrion?
Procyrion has 23 total employees.
-
What industry is Procyrion in?
Procyrion’s primary industry is Therapeutic Devices.
-
Is Procyrion a private or public company?
Procyrion is a Private company.
-
What is Procyrion’s current revenue?
The current revenue for Procyrion is .
-
How much funding has Procyrion raised over time?
Procyrion has raised $117M.
-
Who are Procyrion’s investors?
Bluebird Ventures, Boston Scientific Corporation 401(k) Retirement Savings Plan, NIH Seed, and Fannin have invested in Procyrion.
-
Who are Procyrion’s competitors?
Revamp Medical, Abiomed, NuPulse, Boston Scientific, and Colibri Heart Valve are competitors of Procyrion.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
